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Background: Patients≥ 70 years with small, low-risk breast cancer who are operated but not irradiated how local
relapse rates around 4% after 4 years. With adjuvant whole breast radiotherapy (WBRT) the local relapse rate drops
to 1% after 4 years under Tamoxifen. It has been demonstrated that the efficacy of radiotherapy of the tumor bed
only in a selected group can be non-inferior to WBRT.
Methods/Design: This prospective, multicentric single arm phase II study is based on the protocol of the international
TARGIT-A study. The TARGIT-E study should confirm the efficacy of a single dose of intraoperative radiotherapy (IORT) in
a well selected group of elderly patients with small breast cancer and absence of risk factors. Patients will receive IORT
(20 Gy with Intrabeam system/Carl Zeiss) during breast conserving surgery. In presence of risk factors postoperative
WBRT will be added to complete the radiotherapeutic treatment according to international guidelines. Endpoints are
the local relapse rate (within 2 cm of the tumor bed), ipsilateral in breast relapse, cancer-specific and overall survival and
contralateral breast cancer as well as documentation of quality of life and cosmetic outcome.
The expected local relapse rates are 0.5/1/1.5% after 2.5/5/7.5 years, respectively. Discontinuation of the trial is
scheduled if rates of local relapse rates rise to 3/4/6% after 2.5/5/7.5 years. Power calculations result in 540 patients
with a calculated dropout rate of 20% and loss to follow-up of 20%, an alpha of 0.01 and a beta 0.05. There will be a
pre- and a post-pathology stratum (n= 270 each).
Discussion: It is a pragmatic trial in which each participating centre has the option to modify entry criteria and criteria
for WBRT according to this core protocol after consultation with the steering committee and local ethics committee
(e.g. size, free margins). Only centers with access to the Intrabeam system (Carl Zeiss) can recruit patients into the trial.
Its aim is to confirm the efficacy and toxicity of IORT in a well selected collective of elderly patients with breast cancer.
Trail registration: NCT01299987Background
Randomized studies provide evidence that concerning
the overall survival, breast conserving surgery (BCS)
combined with postoperative radiotherapy is equally
effective to modified radical mastectomy [1-3]. Post-
operative radiation significantly decreases the local
relapse rate [1,2] in comparison to BCS alone [3]. The
recent metaanalysis of the Early Breast Cancer Trialists
Collaborative Group (EBCTCG [3]) shows that the* Correspondence: christian.neumaier@umm.de
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reproduction in any medium, provided the origavoidance of 4 local relapses after 5 years can prevent
one death in 15 years (4 to 1 rule).
Several studies have demonstrated in the past that
complete omission of radiotherapy failed in terms of
local tumor control. Fyles et al. [4] showed local relapse
rates of 8% within a low risk group of patients with
tumors of pathological stage T1/T2 and >50 years of age
treated with BCS and antihormonal treatment (AHT). By
adding postoperative whole breast radiation (WBRT) the
rate of local relapse was reduced to 1% after 5 years. This
effect was also seen in elderly patients with small tumors.
Hughes et al. [5] observed low local relapse rates of 4%
for patients treated with AHT only after BCS vs. 1% forntral Ltd. This is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
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low-risk group of patients with tumors< 2 cm and> 70
years of age. Apparently, all patients benefit from post-
operative WBRT. However, due to the fact that up to
90% of all local relapses after breast conserving therapy
are localized very close to the primary tumor, it might be
possible to treat a selected group of patients with a
relatively low risk of local recurrence with tumor bed
irradiation only. Polgar et al. [6] provided evidence of the
non-inferiority of accelerated partial breast irradiation
(APBI) in comparison to WBRT in a small randomized
trial. Very recently the TARGIT-A data [7] reported a non-
inferior efficacy of tumor bed irradiation with single dose
intraoperative radiation (Intrabeam system, Carl Zeiss
Oberkochen) compared to WBRT regarding local relapse.
By using the Intrabeam system, the intraoperative
radiotherapy (IORT) can be given during surgery with
protection of the surrounding tissue while applying a
biologically highly effective dose to the tissue adjacent to
the tumor. Advantages of IORT are its high precision
regarding beam application, possibility of protection of
the skin and the prevention of tumor cell proliferation
during the time interval between surgery and adjuvant
WBRT and during fractionated WBRT. By manually
positioning of the applicator in the tumor bed geo-
graphic miss is excluded and radiation exposure of risk
structures like the heart and lung can be avoided. There-
fore, it is possible to give a single high dose to the target
while minimizing relevant side effects.
Methods/Design
Study design
This prospective, international, multicentric single arm
phase II study is based on the protocol of the international
TARGIT-A study. The TARGIT-E study should confirm
the efficacy of a single dose of intraoperative radiotherapy
(IORT) in a well selected group of elderly patients with
small breast cancer and absence of risk factors. Patients
treated with breast conserving surgery and IORT will only
be followed by WBRT when risk factors are present. There
will be a pre- and a post-pathology stratum.
Pre-pathology stratum
Patients will enter the trial after careful clinical examin-
ation according to the inclusion criteria. Patients who
are planned to have IORT at the time of primary surgery
will be addressed in this stratum after giving consent
prior to the planned surgery. Additional post-operative
WBRT is given only when risk factors are present. This
stratum will be closed after 270 patients are treated.
Post-pathology stratum
Patients will be recruited for entry to the trial only once
the pathological characteristics of the tumor have beenreported. These patients will have local surgery as per
usual practice and if the patient and the tumor fit in the
criteria defined in the protocol and the investigator’s
treatment policy, she will be asked for consent to enter
the trial and if given she will have further surgery at
which the wound is opened, the probe inserted and the
radiation dose given. This stratum of patients addresses
a much more explanatory question as their entry to the
trial will be strictly defined on pathological grounds.
However, the disadvantage for these patients is that they
must have a second surgery. Including these patients will
allow an assessment of the local control obtained in very
good prognosis patients.
This strategy also allows for the entry of patients who
have already received surgery at an outlying centre. The
post-pathology stratum will recruit 270 patients.
Trial design
The treatment schedule of this single arm phase II study
is shown in the study flow chart (Figure 1).
Recruiting
first patient: January 2011
last patient: December 2015
follow-up: 10 years
Study objectives
The objective of this single armed phase II study is to
investigate the efficacy of a single intraoperative radio-
therapy treatment within elderly low risk patients
(≥ 70 years, cT1 and small cT2, cN0, cM0, invasive-
ductal) which is followed by WBRT only when risk fac-
tors are present. For both primary and secondary efficacy
measures descriptive statistics will be calculated and
Kaplan-Meier plots will be generated. There will be a
separate subgroup analysis of the pre- and post-
pathology strata performed according to primary and
secondary endpoints.
Primary objectives
The primary objective is the rate of local relapse
(within 2 cm around the tumor bed).
Secondary objectives
The secondary objectives are ipsi- or contralateral breast
cancer, cancer specific and overall survival, cosmetic
outcome and quality of life.
Patient selection
Population
Elderly patients (≥ 70 years) with histologically verified
unifocal (mammography, ultrasound), ductal-invasive,
small (≤ 3.5 cm) breast cancer without clinical signs of
lymph node involvement or distant metastases.
TARGIT-E(lderly)
Intraoperative radiotherapy (IORT) in elderly patients
















Systemic therapy according consensus giudelines (St. Gallen)
EIC – extensive intraductal component, WBRT – whole breast radiotherapy, SNB – sentinel node-biopsy,
BCS – breast conserving surgery L1 – lymphangio invasion
*modifications according to local protocols and national guidelines;  **with reference to national guidelines















Additional percutaneous WBRT 46 Gy
(pN1 50Gy, pN2 50 Gy
incl.lymphatic drainage)
Figure 1 Systemic therapy according consensus giudelines (St. Gallen). EIC – extensive intraductal component, WBRT – whole breast radiotherapy,
SNB – sentinel node-biopsy, BCS – breast conserving surgery L1 – lymphangio invasion *modifications according to local protocols and national
guidelines; **with reference to national guidelines a re-resection should be performed in presence of positive resection margins (e.g. <1cm in Germany).
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– histologically verified invasive-ductal breast cancer
– cT1 or small cT2 (≤ 3.5 cm) cN0 cM0




– extensive intraductal component (EIC)– multifocality/-centricity (mammography, breast
ultrasound)
– lymph vessel invasion (L1)
– clinical signs of distant metastases or clinically
suspicious lymph nodes
– other histology
– < 70 years
– missing informed consent or non-compliance
– bilateral breast cancer at the time of diagnosis
– known BCRA1/2 gene mutations (genetic testing
not required)
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treatment policy
– positive resection margins (regarding the
post-pathology arm)
Treatment planning and dose prescription
Radiologic diagnostics
All patients with primary breast cancer receive standar-
dized staging.
– Clinical examination, particularly breast and axilla
palpation
– Mammography and/or ultrasonography of the breast
and histological verification of breast cancer
– Breast magnetic resonance imaging is not required
Surgery
All patients will have local excision of the primary tumor
following appropriate clinical work-up. Surgery will be
performed according to usual local practice with a
complete excision of the tumor. The aim of the local
excision should be to achieve a free margin of at least
10 mm whilst maintaining a good cosmetic outcome.
The final histological margin should be at least 1 mm
clear of all invasive and at least 2 mm for in-situ disease,
otherwise a re-resection is recommended (may be modi-
fied according to local practice). For superficial tumors
an ellipse of overlying skin should be excised to avoid
overdosing of the skin. The depth of resection will
depend on the position of the tumor within the breast
and the size of the breast, but in many instances will
extend to the pectoral fascia. In all patients, but espe-
cially in those women with non-palpable tumors with
mammographic correlate in whom preoperative wire
localization has been performed, the specimen should be
well orientated with sutures or clips according to local
protocols and x-rayed intraoperatively. The specimen
x-ray should be examined in theatre to ensure complete
excision of the lesion and to help with the assessment of
adequacy of the margins. Further tissue should be taken
(and marked) from a margin if the x-ray abnormality
extends near the margin. It is recommended that intrao-
perative evaluation of the resection margin is performed
by fast frozen sections by the pathologist. A standard
sentinel node biopsy must be performed in all patients.
Wound closure must be performed meticulously (air and
water-tight) and sutures (if non-absorbable), should
remain in place for 5–7 days.
Radiotherapy—IORT dose prescription and delivery
The surgeon and radiation oncologist should choose the
largest possible suitable applicator in order to ensure that
the highest possible dose is delivered to the tumor bed
tissue.A dose of 20 Gy at the surface of the applicator (in
water) is prescribed by the radiation oncologist and
delivered to the breast tissue. This takes approximately
20–50 minutes, depending on the size of the applicator.
To minimize radiation induced side effects at the
applicator surface and the skin, the distance should be
more than 5 mm.
During the radiation treatment, the anesthesiologist,
surgeon, radiation oncologist and physicist may remain
in the room when necessary. To avoid unnecessary
exposure, we recommend that as many people as possible
leave the operating theatre, and those remaining either
wear a leaded apron or remain behind a shielded screen.
Conventional radiotherapy (WBRT)
If the final histopathological report provides evidence of
risk factors as per local protocol (e.g. EIC, L1, mulitfocal-
ity/-centricitiy, larger diameter, other histology or too
small free resection margins), a conventional post-
operative percutaneous radiotherapeutic treatment with
WBRT with 46 Gy will be added in 2 Gy per fraction.
WBRT with 50 Gy will be performed in pN1 and WBRT
including irradiation of the lymphatic drainage areas
with 50 Gy in ≥pN2 situations. A delay of at least 5 weeks
is required between IORT and initiation of WBRT. A
delay of at least 14 days (21 days recommended) is
required between chemotherapy and initiation of WBRT.
Adjuvant treatment
Adjuvant systemic treatment will be performed according
to international guidelines.
Trial documentation, schedule and follow-up
Documentation and follow-up
First Visit
Before treatment the general medical history report
forms have to be filled out including the following items:
– anamnesis (height, weight, general condition,
Karnofsky index, medical history)
– Localization of the tumor (mammography,
ultrasound), if palpable (drawing)
– histology (if already available)
– quality of life assessment
– - photo documentation (3 pictures, at 1 m
distance—arms/hands on hips en face, and arms
elevated en face + lateral from side of surgery)
Follow up
Follow-up visits will be scheduled after 6 weeks,
4.5 months, 6 months and annually after radiotherapy.
Photographic documentation and assessment of quality
of life will be performed at follow-up visits as well as
documentation of general condition, weight, new symp-
toms according to CTC and LENT SOMA score.
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breast will be performed according to international
guidelines.
Acute side effects in patients, who received post-
operative WBRT, will be documented by the CTC score.
The follow-up and documentation of patient specific
data will end after 10 years after therapy.
Protocol deviation
Every protocol deviation has to be defined and docu-
mented for every patient.
The investigator has to consult the principle investiga-
tors, to discuss the type and amount of deviation and
their possible consequences for the patient.
Assessment of efficacy parameters
Relapse
At each follow-up visit there will be a clinical
examination to assess local relapse (within 2 cm
around the tumor bed) by palpation. Relapses more
than 2 cm distant from the tumor bed will count as
an ipsilateral relapse. Therefore mammography and
ultrasound of the breast will be performed according
to international guidelines.
Quality of life
To assess the quality of life two standardized, validated
questionnaires of the EORTC (QLQ-C30 version 3.0 and
BR23) will be used before IORT and documented during
follow-up visits. The two questionnaires contain 53
questions and require about 10 minutes to be completed.
Assessment of safety parameters
Classification and graduating of side effects are rated by
“Common Toxicity Criteria” (CTC) of the National
Cancer Institute (Bethesda/USA). If necessary photo
documentation should capture acute toxicities to give
suitable follow-up. The acquisition of late toxicities will
be done based on the LENT SOMA score.
Serious adverse events (SAE)
Serious adverse events (SAEs) are defined as any event
that is fatal, life threatening, causes or prolongs hos-
pitalization; causes disability or incapacity or requires
medical intervention to prevent permanent impairment
or damage, or any grade 4 toxicity.
In case of death an autopsy should be done to clarify
the cause of death.
Regarding the comorbidity of elderly patients only
radiation related SAEs (rrSAEs) grade 4 and 5 including
date and on-/offset should be reported. Furthermore
rrSAEs requiring therapy should be documented (e.g.
antibiotics, aspiration).Statistical calculations for trial sample size
Study hypothesis
This study is designed to confirm the non-inferiority of
IORT in comparison to WBRT in elderly patients with
low risk breast carcinoma.
Power calculations with an alpha set at 0.01, a beta set at
0.05 (power 95%), and an anticipated drop-out rate of 20%
and a loss to follow-up of 20% result in 540 patients to be
included. Calculations of the sample size were performed
as described by A’Hern [8], Simon [9] and Fleming [10].
Each stratum has to recruit at least 270 patients.Description of the primary efficacy analysis and
population
A single group of patients is studied. The proportion of
patients who respond to treatment (i.e. local relapse free)
will be used to estimate the true response rate with a
95% confidence interval. A response rate of 99.5%/99%/
98.5% at 2.5/5/7.5 years is anticipated. A response rate of
97%/96%/94% is considered to be the minimum level.
Therefore, efficacy analyses will be performed at two stages.Planned interim analysis
The first after 144 patients and the second after 386
patients were treated. The expected local recurrence rate
is 0.5/1/1.5% after 2.5/5/7.5 years, respectively. Stopping
rules for the study are if the local recurrence rate is
higher than 3/4/6% after 2.5/5/7.5 years. Therefore the
efficacy of IORT will be rejected if more than 5 or> 8
patients show a local relapse, respectively.
An interim analysis of late breast toxicity is planned
after a two-year follow-up of the first 144 patients.
Results will be presented as frequency tables.Data handling, storage and archiving of date
Data archiving
The responsible physician of the participating trial centre
stores the vote of the ethics commission (copy), patient-
identification list, patient informed consent and patient
related data as well as the protocol in the Investigator’s
Study File (ISF). During audits the primary data have to
be accessible. After closing the trial, the ISF, all source
data and documents have to be stored according to local
legal regulation and ICH-GCP guidelines. The duration
of storage in each centre is at least 30 years.Good clinical practice (GCP)
The physician is responsible that the accomplishment
of the trial will be in concordance with the declar-
ation of Helsinki, revised version of Somerset West,
South Africa 1996 and the guidelines for good clinical
praxis (ICH-GCP).
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To ensure quality, there will be an annual inspection
at the trial centre sites by a study nurse or an investi-
gator. Therefore, it will be obligatory to have insights
in the trial investigation folder to evaluate the proper
documentation and storage of the source data and
CRFs according integrity, completeness of data and
control of the dosing. A source data verification will
be performed after recruiting the first three patients
and will be annually checked by random samples.
Audit
Trial centers, which do not have gathered experience
with IORT during the TARGIT A trial will be inspected
after 5 patients were treated by a physician and a physi-
cist of the trial control center. This audit is to certify the
correct application of IORT. Therefore, the responsible
physician is obliged to present all trial related data to the
auditors (see data archiving).
Auditors will schedule the appointment in order to be
present when a patient will be treated according to the
TARGIT-E protocol and to affirm the correct perform-
ance. Trial centers, which have already been audited
during TARGIT-A, are excluded.
Ethics, informed consent and safety
Ethical aspects
This present study is subjected to supervision of the
Ethics Commission of the Medical Faculty Mannheim,
University of Heidelberg, Germany and the Bundesamt
für Strahlenschutz (BfS).
The informed consent is performed written and verbally
by the responsible physician. The patient has to have
enough time (24 h) to decide whether she participates or
not. During the education the physician has to indicate
that a withdrawal is possible at each time and does not
result in disadvantages for the patient.
Safety
An interim analysis of late breast toxicity is planned after
a two-year follow-up of the first 144 patients. Results will
be presented as frequency tables.
Discontinuation of the trial
Individual withdrawal
The treatment should be stopped, according to the
following criteria:
– Withdrawal of informed consent
– Lack of compliance
– Other required discontinuation of treatment due to
insufficient skin-surface distance (< 5 mm) or
unfavorable geometry will be decided by the physician.
– The reasons for each withdrawal must be documented.Investigator withdrawal
The steering committee is allowed to close the study
ahead of schedule.
Other stop-criteria might be:
– Insufficient recruitment
– Unexpected high toxicity
– Any grade V toxicity
– More than 3 grade IV toxicities within the first 20
patients
– More than 5 grade IV toxicities within the first 50 patients
– Ethical and medical considerations with regard to
new evidence (benefit/risk ratio).
– More than 5 local relapses after the first safety report
Disscussion
The TARGIT-A trial has shown the non-inferiority of
partial breast radiation via the Intrabeam© system as an
IORT compared to WBRT in patients with low risk
breast carcinoma. This international, multicenter, pro-
spective single arm study shall confirm the efficacy of
IORT in elderly patients with low risk breast carcinoma.
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